Home » Stocks » GSK

GlaxoSmithKline plc (GSK)

Stock Price: $37.75 USD 0.06 (0.16%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $37.51 -0.24 (-0.64%) Apr 16, 7:51 PM
Market Cap 93.36B
Revenue (ttm) 46.71B
Net Income (ttm) 7.88B
Shares Out 2.52B
EPS (ttm) 3.15
PE Ratio 12.00
Forward PE 13.77
Dividend $0.80
Dividend Yield 2.12%
Trading Day April 16
Last Price $37.75
Previous Close $37.69
Change ($) 0.06
Change (%) 0.16%
Day's Open 37.82
Day's Range 37.62 - 37.90
Day's Volume 7,972,537
52-Week Range 32.26 - 41.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

It looks like GlaxoSmithKline PLC (NYSE:GSK) has poked the bear.

1 hour ago - GuruFocus

It looks like GlaxoSmithKline PLC (NYSE:GSK) has poked the bear.

1 hour ago - GuruFocus

The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.

Other stocks mentioned: VIR
2 days ago - Zacks Investment Research

"I think that the left-behind health care stocks are now coming back to life at the expense of the cyclical growth plays," the "Mad Money" host said.

Other stocks mentioned: JNJ, LLY, REGN, UNH
2 days ago - CNBC

An activist investor is reportedly building a significant position in the drugmaker.

3 days ago - The Motley Fool

GlaxoSmithKline plc (NYSE: GSK) announced the termination of the Phase II and Phase III studies of feladilimab, its ICOS receptor agonist in head and neck cancer. This comes as a disappointment, as the ...

3 days ago - Benzinga

GlaxoSmithKline gained Thursday on a report activist investor Elliott Management has built a "significant" stake in the pharmaceutical giant. In early action, GSK stock gapped up.

3 days ago - Investors Business Daily

GlaxoSmithKline PLC (LON:GSK) is on the radar of hedge fund group Elliott Management Advisers, according to a report today. The activist fund manager has acquired what was described as a significant sta...

3 days ago - Proactive Investors

Activist hedge fund Elliott Management has taken a multi-billion pound stake in British pharmaceutical firm GlaxoSmithKline, the Financial Times reported on Thursday.

3 days ago - Reuters

The small biotech is getting critical help from a big pharma company.

1 week ago - The Motley Fool

One of the three clearly has the most upside potential.

Other stocks mentioned: LLY, VIR
1 week ago - The Motley Fool

Cheap, solid stocks may seem like a mirage considering the equity bull run, but several excellent investments are trading at a discount. The post 7 Cheap Stocks That Won't Be on Discount for Long appear...

Other stocks mentioned: BGFV, CTO, EQC, INTU, JD, LINC
1 week ago - InvestorPlace

There are five billion reasons these companies hope it's not.

Other stocks mentioned: SNY
2 weeks ago - The Motley Fool

Royalty Pharma Plc (NASDAQ: RPRX) has acquired a royalty interest in Cabometyx and Cometriq from GlaxoSmithKline Plc (NYSE: GSK) for an upfront payment of $342 million. Under this transaction's terms, R...

Other stocks mentioned: RPRX
2 weeks ago - Benzinga

GlaxoSmithKline PLC (LON:GSK) announced it will help produce up to 60mln doses of the Coronavirus (COVID-19) vaccine candidate (NVX-CoV2373) developed by Novavax, Inc. (NASDAQ:NVAX). The FTSE 100 firm s...

Other stocks mentioned: NVAX
2 weeks ago - Proactive Investors

GlaxoSmithKline PLC (LON:GSK) announced it will help making up to 60mln doses of the COVID-19 vaccine candidate (NVX-CoV2373) developed by Novavax, Inc. (NASDAQ:NVAX). The FTSE 100 firm signed an agreem...

Other stocks mentioned: NVAX
2 weeks ago - Proactive Investors

GlaxoSmithKline Plc (NYSE: GSK) has agreed to handle the final part of the manufacturing process for up to 60 million doses of Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine for use in the U.K. GSK will ...

Other stocks mentioned: NVAX
2 weeks ago - Benzinga

These 7 high-yield dividend stocks have yields above 5% and their payout ratios broadly look strong enough to support those dividends. The post 7 High-Yield Dividend Stocks With Enough Earnings to Cover...

Other stocks mentioned: BHP, EC, FANH, T, WPC, XOM
2 weeks ago - InvestorPlace

The following three stocks have underperformed the broader market recently. They are also in considerable financial distress, as represented by poor Altman Z-Scores, meaning they are in danger of going ...

Other stocks mentioned: DEA, HNP
3 weeks ago - GuruFocus

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investi...

Other stocks mentioned: VIR
3 weeks ago - Benzinga

GlaxoSmithKline and Vir Biotechnology applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.

Other stocks mentioned: VIR
3 weeks ago - CNBC

Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing ...

Other stocks mentioned: BMY, CLVS, IMMP, ITRM, NNVC, NVS
3 weeks ago - InvestorPlace

GlaxoSmithKline fired Dr. Moncef Slaoui from the board for Galvani Bioelectronics on Wednesday on allegations he sexually harassed a GSK employee. In response, GlaxoSmithKline stock dipped.

3 weeks ago - Investors Business Daily

GlaxoSmithKline PLC (LON:GSK) announced it has fired Moncef Slaoui as chair of Galvani Bioelectronics, a chronic disease research firm where it is the majority shareholder. Slaoui is the former head of ...

3 weeks ago - Proactive Investors

Moncef Slaoui, former chief scientist of Operation Warp Speed during the Trump administration, was fired as Galvani Bioelectronics' board chairman over “substantiated” sexual harassment allegations by a...

3 weeks ago - Benzinga

Glaxosmithkline said that Moncef Slaoui has been dismissed as chairman of Galvani Bioelectronics, which is majority owned by GSK.

3 weeks ago - Reuters

With the trading day about halfway over, the broad markets had pulled back slightly.

Other stocks mentioned: DKNG, LUV, NFLX, ALXN, BURL, INO, MDB ...
3 weeks ago - 24/7 Wall Street

Other stocks mentioned: BMY, MRK, PFE, VTRS
3 weeks ago - GuruFocus

According to the High Dividend Yield Stocks page, a Premium feature of GuruFocus, five stocks with a dividend yield of at least 4% and double-digit guru buys over the past few months are AbbVie Inc. (NY...

Other stocks mentioned: ABBV, CVX, GILD, XOM
4 weeks ago - GuruFocus

Glaxo (GSK) is developing an anti-IL-5 monoclonal antibody candidate, GSK3511294 - engineered for high affinity and long-acting suppression of IL-5 function - for treating severe asthma patients.

4 weeks ago - Zacks Investment Research

Privately-held Boston Pharmaceuticals has announced a three-year out-license and option agreement with GlaxoSmithKline Plc (NYSE: GSK) to advance pre-phase 2 programs. Initially, GSK will out-license an...

1 month ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK). Boston Pharmaceuticals will b...

1 month ago - Business Wire

Vectura Group PLC (LON:VEC) said it will pay a special dividend of £115mln during 2021 after receiving millions from GlaxoSmithKline PLC (LON:GSK) regarding a US patent litigation. The FTSE 250 pharma c...

1 month ago - Proactive Investors

GlaxoSmithKline PLC (LON:GSK) has started Phase 3 clinical testing of a plant-derived COVID-19 vaccine candidate developed by Canadian partner Medicago. Takashi Nagao, Medicago's chief executive, said: ...

1 month ago - Proactive Investors

GlaxoSmithKline Plc (NYSE: GSK) hopes for better luck with its second partner Medicago, after tripping up in a recent COVID-19 vaccine test with Sanofi SA (NASDAQ: SNY).  GSK and Medicago will start Pha...

1 month ago - Benzinga

QUEBEC CITY & LONDON--(BUSINESS WIRE)--Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate

1 month ago - Business Wire

The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.

Other stocks mentioned: SNY, TBIO, MRNA
1 month ago - Zacks Investment Research

Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.

1 month ago - Zacks Investment Research

GlaxoSmithKline (GSK) closed at $35.55 in the latest trading session, marking a -0.14% move from the prior day.

1 month ago - Zacks Investment Research

GlaxoSmithKline and Vir Biotechnology said Wednesday their antibody drug reduced the risk of hospitalization and death in high-risk Covid-19 patients — and Vir stock catapulted Thursday. The post Vir St...

Other stocks mentioned: VIR
1 month ago - Investors Business Daily

An Independent Data Monitoring Committee (IDMC) has recommended that the Phase 3 COMET-ICE trial, evaluating VIR-7831 (GSK4182136) as monotherapy for COVID-19, stop enrollment due to evidence of profoun...

Other stocks mentioned: VIR
1 month ago - Benzinga

GlaxoSmithKline PLC (LON:GSK) said an independent data monitoring committee (IDMC) recommended to stop the final phase of trials on a COVID-19 treatment because it's very effective. VIR-7831 is a monocl...

1 month ago - Proactive Investors

The relationship could result in a marriage down the line.

Other stocks mentioned: VIR
1 month ago - The Motley Fool

The biotech's pipeline gets a seal of approval.

Other stocks mentioned: VIR
1 month ago - The Motley Fool

It's a real possibility.

Other stocks mentioned: SNY
1 month ago - The Motley Fool

Emerging data cast doubt on the effectiveness of Vir Biotechnology and GlaxoSmithKline's Covid-19 treatment, leading Vir stock to plummet Wednesday. Shares fell more than 27%.

1 month ago - Investors Business Daily

The market is starting to get volatile again and sector rotation is underway. Clear the decks by dumping these stocks to sell for March.

Other stocks mentioned: BIIB, BSX, DUK, LVS, RTX, T
1 month ago - InvestorPlace

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Other stocks mentioned: AZN, BNTX, GILD, ILMN, JNJ, LLY, MRNA ...
1 month ago - Investors Business Daily

GlaxoSmithKline PLC (LON:GSK) said it is tweaking clinical studies on a COVID-19 treatment candidate after missing the primary goal. Otilimab, a monoclonal antibody, did not make a significant differenc...

1 month ago - Proactive Investors

Sanofi and GlaxoSmithKline PLC (LON:GSK) have announced details of a phase II study for their collaborative coronavirus vaccine. Britain's Glaxo and France's Sanofi are the world's two largest vaccine c...

Other stocks mentioned: SNY
1 month ago - Proactive Investors

About GSK

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, ... [Read more...]

Industry
Drug Manufacturers-General
Founded
1715
CEO
Emma Walmsley
Employees
94,066
Stock Exchange
NYSE
Ticker Symbol
GSK
Full Company Profile

Financial Performance

In 2020, GSK's revenue was 34.10 billion, an increase of 1.02% compared to the previous year's 33.75 billion. Earnings were 5.75 billion, an increase of 23.77%.

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is 46.57, which is an increase of 23.36% from the latest price.

Price Target
$46.57
(23.36% upside)
Analyst Consensus: Buy